Other

Alnylam Pharmaceuticals·Income Statement·32 metrics

Breakdown

Loading...

Metrics

Capital Expenditures

Change in Accounts Receivable

Change in Deferred Revenue

OCI Unrealized Holding Gain (Loss) on Securities, Net of Tax

Unrealized Gain (Loss) on Securities

Income Taxes Paid, Net

Interest Paid, Net

OCI Unrealized Holding Gain (Loss) on Securities, Net of Tax

Capital investments accrued but not yet paid

Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Deferred taxes

Depreciation, Amortization and Accretion, Net

Income Taxes Paid, Net

Increase (Decrease) in Accounts Receivable

Increase (decrease) in contract liabilities and current deferred income

Increase (Decrease) in Inventories

Increase (Decrease) in Prepaid Expense and Other Assets

Interest Expense Nonoperating

Interest Paid, Excluding Capitalized Interest, Operating Activity

Cash Provided by (Used in) Financing Activity, Including Discontinued Operation

Cash Provided by (Used in) Investing Activity, Including Discontinued Operation

Cash Provided by (Used in) Operating Activity, Including Discontinued Operation

Net unrealized gains (losses) on securities still held

Other income, net (Note 6)

All other operating activities

Payments to Acquire Debt Securities, Available-for-Sale

Payments to Acquire Property, Plant, and Equipment

Payments to Acquire Restricted Investments

Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options

Revenue

Stock-based compensation

Other Comprehensive Income (Loss)